RxDoctor Payments Data

David Fishman, MD

Interventional Cardiology · Dalton, GANPI 1437386430

Payments from drug & device makers

$1,936in general payments, 2019–2025

Across 63 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$317
  • Shockwave Medical, Inc$262
  • Novartis$249
  • Abiomed$205
  • Chiesi USA, Inc.$176
  • Heartflow, Inc.$137
  • plus $589 from 13 others

What the payments were for

  • Travel & lodging$1176%
  • Food & beverage$1,81094%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,936 in reported general payments places this provider in the 10th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$147,081
Medicare patients
524
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$341,682
EntrestoSacubitril/Valsartan69$85,883
XareltoRivaroxaban47$61,089
Repatha SureclickEvolocumab50$40,787
FarxigaDapagliflozin Propanediol42$35,641
JardianceEmpagliflozin31$35,477
BrilintaTicagrelor42$31,038
Ranolazine ErRanolazine92$11,987
Atorvastatin Calcium470$4,944
Metoprolol Succinate298$3,721
Rosuvastatin Calcium259$3,212
ClopidogrelClopidogrel Bisulfate239$2,522
Isosorbide Mononitrate ErIsosorbide Mononitrate184$2,123
Losartan Potassium176$1,647
Torsemide73$1,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$341,682305 claims
NovartisEntresto$249$85,88369 claims
AstraZenecaFarxiga, Brilinta$117$66,67984 claims
Johnson & JohnsonXarelto$35$61,08947 claims
Boehringer IngelheimJardiance$50$35,47731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →